- A panel of U.S. Food and Drug Administration advisers voted in favor of Ferring Pharmaceuticals' fecal transplant-based therapy to reduce recurrent infections caused by a bacteria known as C. difficile.
The therapy is based on the concept of replenishing the good gut bacteria through samples of microbes distilled from faeces of healthy donors, delivered through an enema in this case.
(Reporting by Manas Mishra and Raghav Mahobe in Bengaluru; Editing by Shinjini Ganguli)